久吾高科 reported revenue of ¥0.30B for the period ended 2026-06-30, +10.5% year on year. Net income was ¥0.04B, a 12.5% net margin on a 36.1% gross margin. The largest revenue line is 膜集成技术整体解决方案及其成套设备 at 67% of the total. Free cash flow for the period was ¥0.04B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.30B | +10.5% |
| Gross profit | ¥0.11B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.04B | -3.3% |
| Gross margin | 36.1% | Net margin 12.5% |
| Revenue Q/Q | +36.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 膜集成技术整体解决方案及其成套设备 | ¥0.20B | 67.0% |
| 材料及配件 | ¥0.10B | 32.8% |
| 其他(补充) | ¥0.00B | 0.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.19B | 63.9% |
| R&D | ¥0.02B | 8.3% |
| SG&A | ¥0.05B | 15.2% |
| Tax & other | ¥0.00B | 0.7% |
| Item | Amount |
|---|---|
| Total assets | ¥2.03B |
| Total liabilities | ¥0.66B |
| Shareholders' equity | ¥1.36B |
| Equity / assets | 67.4% |
| Operating cash flow | ¥0.04B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.04B |
| Cash conversion (OCF / net income) | 33% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
光莆股份 ・ 开立医疗 ・ 彩讯股份 ・ 中达安 ・ 同和药业 ・ 扬帆新材 ・ 广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies